Morgan Stanley lowered the firm’s price target on enGene (ENGN) to $34 from $37 and keeps an Overweight rating on the shares after the company reported Q1 results and provided an update on the LEGEND study of detalimogene. The protocol changes disclosed should help detalimogene demonstrate better durability and further solidify the therapy’s risk/benefit profile for physicians and patients, the analyst tells investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN: